Alzamend Neuro Files 8-K: ISMRT Presentation on Phase 1/2A Clinical Trial

What Happened

• Alzamend Neuro, Inc. (ALZN) filed a Current Report on Form 8-K on September 29, 2026, disclosing that Dr. Ovidiu C. Andronesi — principal investigator on the company’s Phase 1/2A clinical trial and Director of Multinuclear MRI, Martinos Center for Biomedical Imaging (Massachusetts General Hospital), Associate Professor of Radiology at Harvard Medical School — presented at the International Society for MR Radiographers & Technologists (ISMRT) Conference.
• A copy of Dr. Andronesi’s presentation was furnished with the filing as Exhibit 99.1. The company notes that, under Form 8-K General Instruction B.2, the presentation is furnished (not “filed”) for certain legal purposes and is not automatically incorporated by reference into other Securities Act filings.

Key Details

• Date of disclosure/presentation: September 29, 2026.
• Presenter and role: Dr. Ovidiu C. Andronesi, PI on Alzamend’s Phase 1/2A trial; Multinuclear MRI Director, Martinos Center; Associate Professor, Harvard Medical School.
• Presentation included as Exhibit 99.1 to the 8-K (furnished under Form 8-K rules).
• The filing includes the company’s standard forward-looking statements caution advising investors of risks and uncertainties.

Why It Matters

• The 8-K makes presentation materials from a key investigator available to the public, giving investors direct access to information about the company’s Phase 1/2A clinical trial and MRI-related research shared at a scientific conference.
• Because the exhibit is furnished under Regulation FD disclosure rules (not filed for certain legal purposes), investors should review the presentation itself for substantive details; the 8-K does not provide additional trial results or financial metrics.